Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-IPF: deupirfenidone versus pirfenidone in idiopathic pulmonary fibrosis
MOH_2026-10-15_017093Phase 3Recruiting
- Sponsor
- PureTech Health
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing deupirfenidone with pirfenidone (2 arms). Primary endpoint: Primary endpoint not provided in registry entry. Started Jun 2026; status: recruiting.
02
Drugs
deupirfenidonepirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2026-10-15_017093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-15_017093.